ASCO: Sunitinib Alone Noninferior in Metastatic Renal Cell Cancer
MONDAY, June 4, 2018 -- For patients with metastatic renal cell carcinoma classified as having intermediate or poor prognostic risk, sunitinib alone is noninferior to nephrectomy and sunitinib, according to a study published online June 3 in the New...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Nephrectomy | Pharmaceuticals | Renal Cell Carcinoma | Study